Effectiveness
AstraZeneca’s Airsupra Asthma Trial Halted Early Due to Overwhelming Efficacy, Paving Way for Regulatory Submission
AstraZeneca, Airsupra, asthma treatment, clinical trial, overwhelming efficacy, regulatory submission
Novo Nordisk’s CB1 Drug Monlunabant Shows Weight Loss Potential, but Raises Efficacy and Safety Concerns
Novo Nordisk, Monlunabant, CB1 receptor, obesity treatment, weight loss, efficacy, safety concerns, neuropsychiatric side effects
GSK Advances mRNA Flu Vaccine to Late-Stage Clinical Development Following Positive Phase II Results
GSK, mRNA flu vaccine, phase II results, late-stage clinical development, influenza A and B strains, vaccine efficacy, safety profile.
Roche’s Obesity Pill Candidate Faces Safety Concerns Amid Promising Efficacy Results
Roche, Obesity Pill, Safety Concerns, Efficacy Data, CT-996, Side Effects, Nausea, Vomiting, Gastrointestinal Issues
Crestone’s CRS3123 Shows Superior Efficacy in Curing C. difficile Infections and Preventing Recurrence Compared to Vancomycin in Phase 2 Trial
C. difficile infections, CRS3123, Vancomycin, Phase 2 clinical trial, Antibiotic efficacy, Recurrence prevention
Moderna’s Mpox Vaccine Shows Superior Efficacy in Preclinical Study Compared to Approved Version
Moderna, Mpox vaccine, Preclinical study, Superior efficacy, Approved version
Recursion’s Phase 2 Trial for Cerebral Cavernous Malformation Shows Limited Efficacy Despite Meeting Safety Goals
Recursion Pharmaceuticals, Phase 2 trial, cerebral cavernous malformation (CCM), REC-994, safety and tolerability, efficacy data, FDA meeting
Merck’s Ebola Vaccine Demonstrates 84% Effectiveness in Real-World Setting During DRC Outbreak
Ebola vaccine, Merck, Ervebo, effectiveness, real-world analysis, DRC outbreak, vaccination, public health.
FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website
Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment
Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review
Nuvation Bio, BET inhibitor, NUV-868, Phase 1 data, oncology drug, safety and efficacy, clinical trials